DMTTF - Cybin's Deuterated Psychedelics Programs Protected By Three New International Patents | Benzinga
Cybin’s (NYSE: CYBN) deuterated psychedelics programs received two patent grants from the United States Patent and Trademark Office (USPTO,) and one from the European Patent Office (EP.)
Headquartered in Canada and operational in-site as well as in the U.S., the U.K., the Netherlands and Ireland, the clinical-stage psychedelics biopharma company is building a centralized DMT-focused mental health therapies portfolio, consolidating its presence in the space with the recent acquisition of psychedelics biotech Small Pharma (OTCMKTS: DMTTF).
Cybin’s goal of revolutionizing mental healthcare with safe and effective psychedelic-based therapies involves the development of CYB003, a novel deuterated psilocybin analog targeting Major Depressive Disorder (MDD;) and CYB004, a deuterated DMT molecule for Generalized Anxiety Disorder (GAD;) plus advancing a preclinical research pipeline.
Protections’ Extensions
The two U.S. patents on Cybin’s pipeline provide protection ...